Granisetron Kabi Special Precautions

As granisetron may reduce lower bowel motility, patients with signs of sub-acute intestinal obstruction should be monitored following its administration.
As for other 5-HT₃ antagonists, ECG changes including QT interval prolongation have been reported with granisetron. In patients with pre-existing arrhythmias or cardiac conduction disorders this might lead to clinical consequences. Therefore caution should be exercised in patients with cardiac co-morbidities, on cardiotoxic chemotherapy and/or with concomitant electrolyte abnormalities (see Interactions).
Cross-sensitivity between 5-HT₃ antagonists (e.g. dolasetron, ondansetron) has been reported.
This medicinal product contains 1.37 mmol sodium (or 31.5 mg) per maximum daily dose of 9 mg. This should be taken into consideration by patients on a controlled sodium diet.
Serotonin syndrome: Cases of life-threatening serotonin syndrome have been reported with 5-HT₃ receptor antagonist antiemetics, particularly when given in combination with other serotonergic and/or neuroleptic drugs. Treatment should be discontinued if such events occur and supportive symptomatic treatment should be initiated. If concomitant treatment of granisetron with a drug affecting the serotonergic neurotransmitter system is clinically warranted, careful observations of the patient is advised, particularly during treatment initiation and dose increases.
Effects on ability to drive and use machines: Granisetron has no or negligible influence on the ability to drive and use machines.